Organization (Academic)
Eastern Virginia Medical School
ClinicalTrials.gov lists Eastern Virginia Medical School as lead sponsor of 56 trials. It has 14 active development programs and 22 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Wikimedia Commons contributors, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Eastern Virginia Medical School: 56 lead-sponsored trials and 1 legal-entity registration.
Disease areas (93)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 11 |
| Sleep Apnea Syndromes | 6 |
| Sleep Apnea, Obstructive | 5 |
| Diabetic Neuropathies | 4 |
| Premature Rupture of Fetal Membranes | 4 |
Showing 5 of 93 disease areas.
Trials by start year as sponsor or collaborator (23)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 4 |
| 2024 | 2 |
| 2023 | 4 |
| 2022 | 5 |
| 2021 | 11 |
| 2020 | 3 |
| 2019 | 4 |
| 2018 | 2 |
| 2017 | 2 |
Showing 10 of 23 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; 2 of 5 predicted trials reach the 36-month horizon; registered median of 18 months across 32 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (14)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Tranexamic Acid | Metrorrhagia | Phase 3 | 1 |
| Tranexamic Acid | Myofibroma | Phase 3 | 1 |
| Tranexamic Acid | Hemorrhage | Phase 3 | 1 |
| Tranexamic Acid | Leiomyoma | Phase 3 | 1 |
| THC-free CBD Oil | Alzheimer Disease | Phase 2 | 1 |
Showing 5 of 14 active programs.
Approved assets (22)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| DMPA Sub-cutaneous | 1 |
| Use of insulin glargine twice daily | 1 |
| Steroid/Anesthesia Mixture | 1 |
| Use of insulin glargine once daily | 1 |
| Pyridostigmine Bromide 60 Milligrams (mg) | 1 |
Showing 5 of 22 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 36% hit target (n=11) | 23% on time (n=13) |
Journals published in (180)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| American journal of obstetrics and gynecology | 27 |
| Obstetrics and gynecology | 21 |
| The New England journal of medicine | 11 |
| Fertility and sterility | 8 |
| The Cochrane database of systematic reviews | 7 |
Showing 5 of 180 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 52 | 3 | 2025-07-29 |
Financing and grant events (47)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-09-30 | NIH grant | 96,167 | Reporter |
| 2024-09-30 | NIH grant | 11,336 | Reporter |
| 2024-05-31 | NIH grant | 301,350 | Reporter |
| 2023-09-30 | NIH grant | 1,103 | Reporter |
| 2023-06-30 | NIH grant | 375,942 | Reporter |
Showing 5 of 47 events.
Organization relationships (14)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| University of Toronto | Co sponsors trial with | 1 |
| AMAG Pharmaceuticals (United States) | Co sponsors trial with | 1 |
| The Cleveland Clinic | Co sponsors trial with | 1 |
| St. Justine's Hospital | Co sponsors trial with | 1 |
| Alberta Health Services | Co sponsors trial with | 1 |
Showing 5 of 14 relationships.
Latest dated events (179)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-05-18 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-09-30 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-07-29 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 179 events.
CLIA clinical laboratory certificates (4)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| EASTERN VIRGINIA MEDICAL SCHOOL | Certificate for PPM procedures | Active |
| EASTERN VIRGINIA MEDICAL SCHOOL | Certificate of waiver | Active |
| EASTERN VIRGINIA MEDICAL SCHOOL | Certificate for PPM procedures | Terminated |
| EASTERN VIRGINIA MEDICAL SCHOOL | Certificate of waiver | Terminated |
Biomarker capability evidence (60)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AMH | Trial sponsor | Named in trial inclusion criteria |
| BCHE | Trial sponsor | Named in trial inclusion criteria |
| CCNG1 | Trial collaborator | Named in trial inclusion criteria |
| DPP4 | Trial sponsor | Named in trial inclusion criteria |
| PAPOLA | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 60 evidence rows.
Biomarkers this organization publishes on (314)
Shown in this order: most publications first.
Showing 5 of 314 biomarkers.
On Scientist.com
Eastern Virginia Medical School is linked to 2 research suppliers in the Scientist.com network.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, and workforce and board diversity, as filed.
Work with Eastern Virginia Medical School Center for Health Analytics and Discovery (CHAD) on Scientist.com
For prices, more details, or to contact Eastern Virginia Medical School Center for Health Analytics and Discovery (CHAD), visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.